BCM
CHRS icon

Bluefin Capital Management’s Coherus Oncology CHRS Stock Holding History

Bluefin Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-45,000
Closed -$307K – 405
2020
Q1 		$307K Hold
45,000
– – 0.04% 215
2019
Q4 		$248K Buy
+45,000
New +$830K 0.02% 363

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bluefin Capital Management's CHRS Position: Q2 2020 in Review

Bluefin Capital Management sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 29,219 shares — an estimated $474K sold.

Bluefin Capital Management first reported a position in CHRS in Q4 2019 and held it in 2 quarters. The position peaked at $474K in Q1 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

  • Bluefin Capital Management reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
  • Bluefin Capital Management sold 29,219 Coherus Oncology shares in Q2 2020, an estimated $474K.
  • Bluefin Capital Management first reported a position in Coherus Oncology in Q4 2019 and held it in 2 quarters.
  • Bluefin Capital Management's Coherus Oncology position peaked at $474K in Q1 2020.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Bluefin Capital Management's 13F filing for Q2 2020, filed 17 Aug 2020.